{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:26:32Z","timestamp":1758039992846,"version":"3.44.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ahj.2015.11.001","type":"journal-article","created":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T07:48:20Z","timestamp":1446796100000},"page":"42-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?"],"prefix":"10.1016","volume":"172","author":[{"given":"Antonio Eduardo P.","family":"Pesaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2015.11.001_bb0005","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.11.001_bb0010","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.11.001_bb0015","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.11.001_bb0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1568006043586189","article-title":"Statins and thrombin","volume":"5","author":"Fenton","year":"2005","journal-title":"Curr Drug Targets Cardiovasc Haematol Disord"},{"key":"10.1016\/j.ahj.2015.11.001_bb0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11239-007-0154-1","article-title":"Effect of high dose statin therapy on platelet function: statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease","volume":"27","author":"Tirnaksiz","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ahj.2015.11.001_bb0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ahj.2015.11.001_bb0035","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jacc.2008.10.031","article-title":"Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial","volume":"52","author":"Fleg","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2015.11.001_bb0040","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2011.01.062","article-title":"Pleiotropic effects of ezetimibe\/simvastatin vs. high dose simvastatin","volume":"158","author":"Pesaro","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2015.11.001_bb0045","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1074248413489771","article-title":"Increasing doses of simvastatin versus combined ezetimibe\/simvastatin: effect on circulating endothelial progenitor cells","volume":"18","author":"Pesaro","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ahj.2015.11.001_bb0050","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2125.2007.03080.x","article-title":"Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin","volume":"65","author":"Hussein","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2015.11.001_bb0055","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000347134","article-title":"The effects of ezetimibe\/simvastatin versus simvastatin monotherapy on platelet and inflammatory biomarkers in patients with metabolic syndrome","volume":"125","author":"Miller","year":"2013","journal-title":"Cardiology"},{"key":"10.1016\/j.ahj.2015.11.001_bb0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1160\/TH08-06-0385","article-title":"No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance","volume":"101","author":"Malmstr\u00f6m","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2015.11.001_bb0065","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ahj.2007.02.029","article-title":"Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration","volume":"153","author":"Blanco-Colio","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2015.11.001_bb0070","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.jacc.2007.06.057","article-title":"Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial","volume":"50","author":"de Lemos","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2015.11.001_bb0075","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.clinthera.2007.10.004","article-title":"Effects of ezetimibe\/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques","volume":"29","author":"Ose","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.ahj.2015.11.001_bb0080","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1185\/030079907X188062","article-title":"Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia","volume":"23","author":"Kalogirou","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ahj.2015.11.001_bb0085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0014-5793(86)80518-X","article-title":"Lipoprotein-binding proteins in the human platelet plasma membrane","volume":"200","author":"Koller","year":"1986","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ahj.2015.11.001_bb0090","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/09537100020000157","article-title":"The effect of oxidatively modified low-density lipoproteins on platelet aggregability and membrane fluidity","volume":"11","author":"Vlasova","year":"2000","journal-title":"Platelets"},{"key":"10.1016\/j.ahj.2015.11.001_bb0095","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0024-3205(00)00691-3","article-title":"Chronic changes in plasma triglyceride levels do modify platelet membrane microviscosity in rats","volume":"67","author":"Kunes","year":"2000","journal-title":"Life Sci"},{"issue":"Suppl. 1","key":"10.1016\/j.ahj.2015.11.001_bb0100","first-page":"72","article-title":"Aspirin resistance, hyperlipidemia and secondary stroke prevention","volume":"1","author":"Karepov","year":"2006","journal-title":"Int J Stroke"},{"key":"10.1016\/j.ahj.2015.11.001_bb0105","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.bbrc.2004.06.092","article-title":"Cholesterol absorption inhibitor ezetimibe blocks uptake of oxidized LDL in human macrophages","volume":"320","author":"Seedorf","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ahj.2015.11.001_bb0110","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/eurheartj\/ehm226","article-title":"A comparison of sixmajor platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease","volume":"28","author":"Lordkipanidz\u00e9","year":"2007","journal-title":"Eur Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870315006456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870315006456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:55:05Z","timestamp":1757570105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870315006456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":22,"alternative-id":["S0002870315006456"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2015.11.001","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2015.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}